Anti Vegf Eylea 2mg denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti vegf eylea 2mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Eylea (aflibercept 2 mg) for Medical Necessity

A medical-necessity denial from UnitedHealthcare means a clinical reviewer concluded that the submitted documentation did not demonstrate that Eylea 2 mg is the appropriate, medically required treatment for your condition at this time. These denials often occur because clinical notes in the original prior-authorization submission were too brief, lacked objective diagnostic measurements, or did not address the specific clinical criteria in UHC's anti-VEGF coverage policy. The denial is almost always documentation-driven rather than a reflection that the treatment is actually inappropriate.

## Why This Denial Is Appealable

Medical necessity is a legal standard under your plan, not a judgment call insulated from review. If your retinal specialist has documented a qualifying diagnosis, a clinically significant finding on imaging, and a treatment plan consistent with the FDA-approved use of Eylea 2 mg, the standard is met — and the appeal record can prove it. Courts and independent review organizations consistently overturn medical-necessity denials when the clinical record is complete and properly mapped to the plan's own criteria.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer-sponsored plans) or ACA-compliant plan rules, you have a right to a full and fair internal review. File within the deadline on your denial letter.
• External review (ACA §2719): If the internal appeal is denied, you may escalate to an Independent Review Organization within approximately four months of the original denial. The IRO's decision is binding on UHC.
• Expedited review: Request the 72-hour expedited track if continued denial would cause serious harm to your vision or health.

## Documentation to Gather

1. Diagnosis confirmation — ophthalmology notes confirming the active diagnosis (e.g., neovascular AMD, diabetic macular edema, macular edema from retinal vein occlusion) with ICD-10 code matching the claim. 2. Objective findings — OCT imaging reports, best-corrected visual acuity measurements, and any fluorescein angiography results documenting disease activity and severity. 3. Treatment history — a timeline of all prior treatments with dates and outcomes, demonstrating the clinical course leading to the Eylea 2 mg prescription. 4. Prescriber medical-necessity letter — a detailed letter from your retinal specialist explaining why Eylea 2 mg is medically necessary for this patient at this time, explicitly addressing each criterion in UHC's published anti-VEGF coverage policy. 5. UHC coverage policy — download UHC's current published medical policy for anti-VEGF agents; your appeal must address every listed necessity criterion directly.

## Criteria-Mapping Structure

Create a two-column table. Left column: each numbered criterion from UHC's anti-VEGF policy, copied verbatim. Right column: the specific chart note, imaging finding, or prescriber statement that satisfies that criterion, with the date and source document cited. This structure prevents a reviewer from dismissing your appeal as non-responsive and creates a clear record for the IRO if you need external review.